TNXP
Tonix Pharmaceuticals Holding Corp
NASDAQ
| Dec 2025 | Dec 2024 | Dec 2023 | |
|---|---|---|---|
| Revenue | |||
| Revenue | 13.1M | 10.1M | 7.8M |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Operating Expenses | |||
| R&D Expenses | — | — | — |
| SG&A Expense | — | — | — |
| Total Op. Expenses | — | — | — |
| Operating Income | -125.7M | -136.7M | -118.4M |
| EBITDA | — | — | — |
| Below the Line | |||
| Interest Expense | — | — | — |
| Pre-Tax Income | — | — | — |
| Income Tax | — | — | — |
| Net Income | -124.0M | -130.0M | -116.7M |
| Per Share | |||
| EPS (basic) | — | — | — |
| EPS (diluted) | — | — | — |
| Shares | |||
| Basic Shares | — | — | — |
| Diluted Shares | 9M | 1M | 0M |